Eszter Lázár-Molnár | ARUP Laboratories

Eszter Lázár-Molnár, PhD

Eszter Lázár-Molnár, PhD, D(ABMLI), F(ACHI)

Director: Histocompatibility and Immunogenetics Laboratory

Medical Director: Immunology
Associate Professor (Clinical), University of Utah School of Medicine

Education

Doctorate Degree—Cell and Immune Biology, Semmelweis University
Fellowship—Albert Einstein College of Medicine
Fellowship—Research, Cancer Research Institute
Fellowship—Clinical Immunology, University of Utah

Certification/Affiliations

American Board of Medical Laboratory Immunology
American Board of Histocompatibility and Immunogenetics

Research Interests

Immunotherapy, immunogenicity testing for biologics
Transplantation testing, HLA, and disease associations
Immune monitoring, CyTof

Awards

Doctorate Research Award, Semmelweis University, 2001
Belfer Prize for outstanding postdoctoral research, Albert Einstein College of Medicine, 2008
Junior Faculty Travel Award, AAI 97^th Annual Meeting, 2010
Travel Award, AMLI, 27^th Annual Meeting, 2014
Travel Award, CIS 2015 School in Primary Immunodeficiency Diseases
Best Case Study Presentation – BMT, ASHI, 42^nd Annual Meeting, 2016

Recent Publications

Ravkov EV, Charlton CM, Barker AP, et al. Evaluation of mass cytometry in the clinical laboratory. Cytometry B Clin Cytom. 2019;96(4):266-274.
Lázár-Molnár E, Delgado JC. Implications of monoclonal antibody therapeutics use for clinical laboratory testing. Clin Chem. 2019;65(3):393-405.
Pavlov IY, Parker RL, Lázár-Molnár E, et al. Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. J Immunol Methods. 2019;470:33-39.
Lázár-Molnár E, Snyder M. The role of human leukocyte antigen in celiac disease diagnostics. Clin Lab Med. 2018;38(4):655-668.
Profaizer T, Lázár-Molnár E, Pole A, et al. HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: a comparison. Int J Immunogenet. 2017;44(4):164-168.
Lázár-Molnár E, Scandiuzzi L, Basu I, et al. Structure-guided development of a high-affinity human Programmed Cell Death-1: implications for tumor immunotherapy. EBioMedicine. 2017;17:30-44.